1. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome
- Author
-
Daver, N, Kantarjian, H, Ravandi, F, Estey, E, Wang, X, Garcia-Manero, G, Jabbour, E, Konopleva, M, O'Brien, S, Verstovsek, S, Kadia, T, Dinardo, C, Pierce, S, Huang, X, Pemmaraju, N, Diaz-Pines-Mateo, M, Cortes, J, and Borthakur, G
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Oncology and Carcinogenesis ,Rare Diseases ,Orphan Drug ,Hematology ,Pediatric Cancer ,Cancer ,Clinical Research ,Childhood Leukemia ,Clinical Trials and Supportive Activities ,Pediatric ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Good Health and Well Being ,Adult ,Aged ,Aged ,80 and over ,Aminoglycosides ,Antibodies ,Monoclonal ,Humanized ,Antineoplastic Combined Chemotherapy Protocols ,Azacitidine ,Decitabine ,Female ,Gemtuzumab ,Humans ,Leukemia ,Myeloid ,Acute ,Male ,Middle Aged ,Myelodysplastic Syndromes ,Sialic Acid Binding Ig-like Lectin 3 ,Clinical Sciences ,Immunology ,Cardiovascular medicine and haematology ,Clinical sciences ,Oncology and carcinogenesis - Abstract
Decitabine may open the chromatin structure of leukemia cells making them accessible to the calicheamicin epitope of gemtuzumab ozogamicin (GO). A total of 110 patients (median age 70 years; range 27-89 years) were treated with decitabine and GO in a trial designed on model-based futility to accommodate subject heterogeneity: group 1: relapsed/refractory acute myeloid leukemia (AML) with complete remission duration (CRD)
- Published
- 2016